OAKLAND, Calif. (AP) — A jury on Monday ordered agribusiness giant Monsanto Co. to pay a combined $2.05 billion to a couple claiming that the company’s popular weed killer Roundup Ready caused their cancers.
The jury’s verdict is third such courtroom loss for Monsanto in California since August.
The state court jury in Oakland concluded that Monsanto’s weed killer caused the non-Hodgkin’s lymphoma Alva Pilliod and Alberta Pilliod each contracted. Jurors awarded them each $1 billion in punitive damages in addition to compensatory damages.
A federal jury in San Francisco ordered the weed killer maker in March to pay a Sonoma County man $80 million. A San Francisco jury last August awarded $289 million to a former golf course greens keeper who blamed his cancer on Monsanto’s Roundup Ready herbicide. A judge later reduced the award to $89 million.
The three California trials were the first of an estimated 13,000 lawsuits pending against Monsanto across the country to go to trial. St. Louis-based Monsanto is owned by the German chemical giant Bayer A.G.
Bayer said Monday that it would appeal the verdict.
E. coli outbreak: 196 people in 10 states now sick, linked to ground beef
Not just balloons: Helium shortage may deflate MRIs, airbags and research
“The verdict in this trial has no impact on future cases and trials, as each one has its own factual and legal circumstances,” the company said.
The company noted that none of the California verdicts have been considered by an appeals court and that the U.S. Environmental Protection Agency considers the weed killer safe.
The EPA reaffirmed its position in April, saying that the active ingredient glyphosate found in the weed killer it posed “no risks of concern” for people exposed to it by any means — on farms, in yards and along roadsides, or as residue left on food crops.
The lawsuits have battered Bayer’s stock since it purchased Monsanto for $63 billion last year and Bayer’s top managers are facing shareholders discontent.
Chairman Werner Wenning told shareholders at Bayer’s annual general meeting in Bonn last month that company leaders “very much regret” falls in its share price. At the same time, CEO Werner Baumann insisted that “the acquisition of Monsanto was and remains the right move for Bayer.”
Bayer’s stock price closed Monday at $15.91 a share, down 45 cents or 2.76 percent per share, in trading on the New York Stock Exchange. The verdict was announced after the trading session closed.
Bayer’s share price has lost half its value since it reached s 52-week high of $32.80 a share.